CA3011607C - Cdc45l peptides and vaccines including the same - Google Patents

Cdc45l peptides and vaccines including the same Download PDF

Info

Publication number
CA3011607C
CA3011607C CA3011607A CA3011607A CA3011607C CA 3011607 C CA3011607 C CA 3011607C CA 3011607 A CA3011607 A CA 3011607A CA 3011607 A CA3011607 A CA 3011607A CA 3011607 C CA3011607 C CA 3011607C
Authority
CA
Canada
Prior art keywords
peptide
cdc45l
peptides
present
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3011607A
Other languages
English (en)
French (fr)
Other versions
CA3011607A1 (en
Inventor
Yusuke Nakamura
Yasuharu Nishimura
Yusuke Tomita
Takuya Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Priority to CA3167451A priority Critical patent/CA3167451A1/en
Publication of CA3011607A1 publication Critical patent/CA3011607A1/en
Application granted granted Critical
Publication of CA3011607C publication Critical patent/CA3011607C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3011607A 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same Active CA3011607C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3167451A CA3167451A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
US61/217,133 2009-05-26
CA2762934A CA2762934C (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2762934A Division CA2762934C (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3167451A Division CA3167451A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
CA3011607A1 CA3011607A1 (en) 2010-12-02
CA3011607C true CA3011607C (en) 2022-09-13

Family

ID=43222423

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3167451A Pending CA3167451A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same
CA3011607A Active CA3011607C (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same
CA2762934A Active CA2762934C (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3167451A Pending CA3167451A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2762934A Active CA2762934C (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Country Status (16)

Country Link
US (1) US8586547B2 (OSRAM)
EP (4) EP3868778A3 (OSRAM)
JP (1) JP5903697B2 (OSRAM)
KR (1) KR101765452B1 (OSRAM)
CN (3) CN103694315B (OSRAM)
AU (1) AU2010253356B2 (OSRAM)
BR (1) BRPI1010666B1 (OSRAM)
CA (3) CA3167451A1 (OSRAM)
DK (3) DK3208334T3 (OSRAM)
ES (3) ES2875950T3 (OSRAM)
IL (1) IL216211A (OSRAM)
MX (1) MX2011012619A (OSRAM)
RU (1) RU2562160C2 (OSRAM)
SG (1) SG176058A1 (OSRAM)
TW (1) TWI507204B (OSRAM)
WO (1) WO2010137295A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014012363A (en) * 2011-10-28 2014-09-26 Oncotherapy Science Inc Topk peptides and vaccines including the same
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
WO2018138110A1 (en) 2017-01-25 2018-08-02 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
SG11202002520UA (en) 2017-09-19 2020-04-29 Univ British Columbia Anti-hla-a2 antibodies and methods of using the same
JP7317023B2 (ja) 2017-09-20 2023-07-28 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 新規抗ｈｌａ－ａ２抗体、およびその使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US7074897B2 (en) * 1997-06-16 2006-07-11 Genentech, Inc. Pro943 polypeptides
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
WO2002072631A2 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
CN103073620B (zh) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
CN101472943B (zh) * 2006-06-16 2013-07-17 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗

Also Published As

Publication number Publication date
CN105153279B (zh) 2018-09-11
CA2762934A1 (en) 2010-12-02
EP3208334B1 (en) 2019-07-03
BRPI1010666A2 (pt) 2017-09-12
EP3556857B1 (en) 2021-05-05
DK2435567T3 (en) 2017-07-24
AU2010253356A1 (en) 2011-12-01
RU2562160C2 (ru) 2015-09-10
CN102459589A (zh) 2012-05-16
BRPI1010666B1 (pt) 2021-11-23
ES2746334T3 (es) 2020-03-05
KR101765452B1 (ko) 2017-08-07
EP3868778A2 (en) 2021-08-25
WO2010137295A1 (en) 2010-12-02
AU2010253356B2 (en) 2015-09-24
EP3208334A2 (en) 2017-08-23
IL216211A (en) 2016-06-30
US20120164163A1 (en) 2012-06-28
CN103694315A (zh) 2014-04-02
DK3556857T3 (da) 2021-07-12
ES2631952T3 (es) 2017-09-06
EP3868778A3 (en) 2021-11-03
CN103694315B (zh) 2015-07-29
TWI507204B (zh) 2015-11-11
CN105153279A (zh) 2015-12-16
CN102459589B (zh) 2013-12-25
EP2435567A1 (en) 2012-04-04
JP2012527867A (ja) 2012-11-12
CA3167451A1 (en) 2010-12-02
CA2762934C (en) 2018-09-04
JP5903697B2 (ja) 2016-04-20
EP3208334A3 (en) 2017-10-18
ES2875950T3 (es) 2021-11-11
TW201106962A (en) 2011-03-01
SG176058A1 (en) 2011-12-29
EP2435567A4 (en) 2013-03-13
CA3011607A1 (en) 2010-12-02
KR20120018203A (ko) 2012-02-29
IL216211A0 (en) 2012-01-31
DK3208334T3 (da) 2019-09-30
EP2435567B1 (en) 2017-05-03
US8586547B2 (en) 2013-11-19
EP3556857A3 (en) 2019-12-04
RU2011152975A (ru) 2013-07-10
EP3556857A2 (en) 2019-10-23
MX2011012619A (es) 2012-01-30

Similar Documents

Publication Publication Date Title
JP5799394B2 (ja) Ｎｅｉｌ３ペプチドおよびそれを含むワクチン
CA3011607C (en) Cdc45l peptides and vaccines including the same
CA2761393A1 (en) Ttk peptides and vaccines including the same
JP5838482B2 (ja) Ｈｊｕｒｐペプチドおよびそれを含むワクチン
CA2892369A1 (en) Sema5b peptides and vaccines containing the same
HK40057055A (en) Cdc45l peptides and vaccines including the same
HK40015530B (en) Cdc45l peptides and vaccines including the same
HK40015530A (en) Cdc45l peptides and vaccines including the same
HK1242735B (en) Cdc45l peptides and vaccines including the same
HK1166098B (en) Cdc45l peptides and vaccines including the same
HK1166098A (en) Cdc45l peptides and vaccines including the same
HK1242735A1 (en) Cdc45l peptides and vaccines including the same
HK1242735A (en) Cdc45l peptides and vaccines including the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180717

EEER Examination request

Effective date: 20180717

EEER Examination request

Effective date: 20180717

EEER Examination request

Effective date: 20180717

EEER Examination request

Effective date: 20180717